Biotechnology Industry News
This newspage features a selected set of feeds from biotechnology industry information sources.
- Exciting changes1 January 2012, 5:00 am
Full details at the Journal of Commercial Biotechnology ... - EU Legal & Regulatory Update1 January 2012, 5:00 am
Full details at the Journal of Commercial Biotechnology ... - Bacterial proteins: A new class of cancer therapeutics1 January 2012, 5:00 am
Cancer is a complex disease with a network of multiple metabolic pathways that are interlinked to promote growth and resist immune surveillance. Such a network is efficiently maintained through acquisition of multiple mutations in the human genome that result in the escape from normal cellular growth regulation and formation of lumps of fast growing cells known as tumors. The varied pathways through which cancer cells grow and inhibit their own cell death have made it difficult to develop ... - Biomarketing strategy and tactics 101 PART I of III1 January 2012, 5:00 am
The American Marketing Association defines marketing as the activity, set of institutions, and processes for creating, communicating, delivering, and exchanging offerings that have value for customers, clients, partners, and society at large.1 According to the Pharmaceutical Research and Manufacturers of America appropriate marketing of medicines ensures that patients have access to the products they need and that the products are used correctly for maximum patient benefit.2 The most important p...
- Drug Patent Expirations for Feb 5 2012
If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations ADVERTISE HERE This newsletter is a free service of DrugPatentWatchDrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patentsSimple flat-rate database subscription plansUltimate PlanPremium PlanBasic PlanOne year$1,895 $1,695 $975 One month$475 $375 $275 48 hours$95 $75 Plan comparison Site tour &... - Drug Patent Expirations for Jan 31 2012
If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations ADVERTISE HERE This newsletter is a free service of DrugPatentWatchDrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patentsSimple flat-rate database subscription plansUltimate PlanPremium PlanBasic PlanOne year$1,895 $1,695 $975 One month$475 $375 $275 48 hours$95 $75 Plan comparison Site tour &... - Drug Patent Expirations for Jan 29 2012
If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations ADVERTISE HERE This newsletter is a free service of DrugPatentWatchDrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patentsSimple flat-rate database subscription plansUltimate PlanPremium PlanBasic PlanOne year$1,895 $1,695 $975 One month$475 $375 $275 48 hours$95 $75 Plan comparison Site tour &... - Drug Patent Expirations for Jan 24 2012
If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations ADVERTISE HERE This newsletter is a free service of DrugPatentWatchDrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patentsSimple flat-rate database subscription plansUltimate PlanPremium PlanBasic PlanOne year$1,895 $1,695 $975 One month$475 $375 $275 48 hours$95 $75 Plan comparison Site tour &...
- Message: This news feed will stop on Jan 23 2012. Thank you for your custom.30 January 2012, 1:34 pm
Sponsored Link... - Plandai Biotechnology, Inc. Announces Appointment of World-Renowned Physicist to Chair Plandai Scientific Board30 January 2012, 1:34 pm
SEATTLE, WA -- (Marketwire) -- 01/30/12 -- Plandaí Biotechnology, Inc. (OTCBB: PLPL) Chief Executive Officer, Roger Duffield, today announced that Dr. Tom Matula has accepted the position of Chairman of the Scientific Board for Plandaí Biotechnology,... - RBCC Explores New Cures for Cancer, Brain Injuries & Headaches30 January 2012, 10:01 am
of currently incurable diseases from cancer to brain injuries to headaches. Rainbow Coral Corp. (OTCBB:RBCC), an emerging biotechnology company, is hard at work identifying and targeting promising new stem-cell treatments for commercialization. As the... - Relatively High PEG Ratio Detected in Shares of BioMarin Pharmaceutical in the Biotechnology Industry (BMRN, VRTX, LGND, BIIB, MYGN)30 January 2012, 9:58 am
Below are the three companies in the Biotechnology industry with the highest price to earnings to growth (PEG) ratios. PEG is valuable in assessing the tradeoff between the price of a stock and expected growth. Generally, the lower...
- Can Human Genome Really Double Its Stock Price? (HGSI)28 December 2011, 2:30 pm
... - Alimera Implosion Analysis, What Is Next (ALIM, PSDV)11 November 2011, 9:17 pm
... - Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)8 November 2011, 6:58 pm
... - Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)4 November 2011, 3:25 pm
...
- FDA Forecast for 20124 January 2012, 3:48 pm
Expecting something from the FDA is a risky endeavor, and that makes it all the more worthwhile to read the tea leaves every once in a while. *Note: This blog post is excerpted and adapted from Cerulean's special FDA in the New Year issue of our SmarterCompliance regulator intelligence newsletter, a yearly forecast of FDA activities and challenges in the new year along with specific recommendations and suggested activities for quality, regulatory affairs, records management, IT and other complia... - From the Annual Personal Care Products Council Science Symposium28 October 2011, 2:59 pm
Last week, I served as the keynote quality speaker at the international Personal Care Products Council's 2011 Science Symposium in Newark, New Jersey. The turnout was very impressive - every where I went, rooms were packed - more so than any conference I've attended in recent years. A great number of the attendees had a solid grasp of the challenges they faced and were looking for real-world solutions and advice. It's always a good sign when the majority of conference attendees are managers, dir... - Recent 21 CFR 11 Questions & Answers6 September 2011, 8:37 pm
Since FDA announced its intent to vigorously enforce 21 CFR 11, I've collected various questions posed by attendees at my workshops and speeches on 21 CFR 11 compliance. Now, one year later and a year's track record of Part 11-related FDA Warning Letters, I thought it might be time to walk through a few of the most common questions and answers. Hopefully, this will help you stay on the right track when it comes to validating non-product software, computerized systems and Part 11 validation. Q: W... - Results from Annual FDA Supplier Quality Congress15 August 2011, 5:23 pm
Supplier quality management is complicated enough. Yet, too often, we shoot ourselves in the foot, making supplier qualification and oversight more complicated, more removed from business realities than necessary. This was the common theme amongst speakers and attendees at FDAnews' third annual Supplier Quality Management Congress. I was fortunate enought to chair the three day event, from August 9th-11th, with speakers from FDA, pharma and device firms, and suppliers to the industry. To start t...
- Stubborn facts on biotech financing31 January 2012, 4:49 pm
By Kristin Schneeman, Program Director, FasterCures “Facts are stubborn things,” was a saying that originated in the defense of the British soldiers at the Boston Massacre trial, meaning facts are facts and can’t be disputed. But facts can also be stubbornly difficult to interpret sometimes. A new National Venture Capital Association survey was released last week, reporting that venture capital invested in biotech was up in 2011 by 22% from 2010, but that first-roun... - Who decided that “top 10” lists should have 10 things on them?25 January 2012, 8:13 pm
By Kristin Schneeman, Program Director, FasterCures For five years now FasterCures has been producing its “Top 10” list of medical research trends to watch in the coming year. And every year we have to go through the painful process of deciding what to leave on the cutting room floor. We relish the opportunity to tell people about some of the interesting trends, ideas, initiatives, events, and people that we think are worthy of attention in the 12 months ahead. But there is more that we... - On Huffington Post: Top 10 Medical Research Trends to Watch in 20129 January 2012, 9:31 pm
Margaret Anderson, Executive Director, FasterCures 1. NCATS: Who moved my cheese?This year, the National Institutes of Health will establish its new National Center for Advancing Translational Sciences (NCATS), created to speed the translation of basic discoveries into therapies that will improve public health. In light of our current fiscal reality (and limitations), we breathed a sigh of relief to see it up and prioritized in the appropriations process. Solutions can be tough to develop... - Business Is from Mars, Academia Is from Venus4 January 2012, 6:48 pm
Universities are showing increasing interest in stretching their work into the "Valley of Death" to move their discoveries towards treatments. Companies are rethinking their alliances with universities as sources of innovation to fill their pipelines, beyond traditional sponsored research agreements. At the Partnering for Cures meeting in November, experts discussed where such rethinking is taking place, the replicability and scalability of these models, and the challenges of this new type of re...
- Cancer Institute Sues Biotech Company for More than $1 Billion Charging IP Theft27 January 2012, 1:00 pm
A nonprofit cancer research institute has sued biotechnology company Agios and one of its cofounders for more than $1 billion, alleging they took intellectual property developed at the institute and used it to start a for-profit business. The Leonard and Madlyn Abramson Family Cancer Research Institute, part of the Abramson Cancer Center at the University of [...] Related posts: Research Tax Credits and Grants, Capped at $1 Billion, Boon for Small to Mid-sized Biotech Companies Biotech Drugs: Ho... - Who Should Receive a National Medal of Technology and Innovation?26 January 2012, 10:21 pm
The USPTO is seeking nominations for the 2012 Medal of Technology and Innovation (NMTI), the nation’s highest honor for technological achievement, bestowed by the President of the United States on America’s leading innovators. A nomination form and detailed information about submission requirements can be downloaded here. All completed nominations must be submitted to the USPTO [...] Related posts: USPTO to Administer National Medal of Technology and Innovation National Inventors’ ... - Advanced Summit on Medical Device Patents20 January 2012, 10:25 pm
What: American Conference Institute’s Advanced Summit on Medical Device Patents. A medical device specific intellectual property conference to provide you with practical and tactical strategies for patent filings and challenges, which are more critical than ever in this time of sweeping change. In response to the challenges facing the device industry in this daunting economic climate including the [...] Related posts: Medical Device Development 101 Seminar Cleveland Clinic 2007 Innovation Summ... - Book Review Monday: Trademark Surveys20 December 2011, 2:43 pm
“There are three kinds of lies: lies, damned lies, and statistics.” ~British Prime Minister Benjamin Disraeli Surveys are everywhere and poll results are available for every imaginable topic. In the U.S., there were concerns about the admissibility of surveys for hearsay reasons but legislative amendment (Rule 702 of the 1975 Federal Rules of Evidence) eliminated objections, [...] Related posts: Book Review Monday: Patent Litigation in China Book Review Monday: Clean Tech I...
- IP Roundtable on Gene Patenting after Myriad4 February 2012, 5:18 am
Navigant will be hosting a IP roundtable on the "Gene Patenting in the U.S. after Myriad" on February 23, 2012 from 12:00 to 1:30 pm at Navigant's offices in Chicago, IL. The roundtable will be moderated by Thomas J. Filarski of Steptoe & Johnson LLP. There is no registration fee for the roundtable, but those interested in registering for the roundtable can do so here. To encourage maximum interaction, enrollment will be limited to 25 persons. Additional information regarding the roundtable ... - Webinar on Supplemental Examination4 February 2012, 5:14 am
Strafford will be offering a webinar entitled "New Supplemental Examination: USPTO Outlines New Rules" on February 14, 2012 from 1:00 - 2:30 pm (EST). Scott A. McKeown of Oblon Spivak McClelland Maier & Neustadt and Professor Lisa A. Dolak of Syracuse University College of Law will discuss the new supplemental examination proceeding, the mechanics of the procedure and the considerations that may govern decisions to use it over other post grant options. The panel will also examine the ethics ... - Seminar on Invention Disclosures and the AIA4 February 2012, 5:13 am
The Intellectual Property Law Association of Chicago (IPLAC) Patent Agents Committee will be offering a lunch and learn event on "Invention Disclosures and the America Invents Act" on February 17, 2012 from 12:00 to 3:00 pm (Central) in Room 1200A at the John Marshall Law School in Chicago, IL. Timothy J. Engling of Miller Canfield and John P. Wappel of Caterpillar Inc. will discuss invention disclosures and nuances for disclosures related to the America Invents Act. The registration fee for the... - Webinar on Impact of AIA on Patent Valuation4 February 2012, 5:11 am
The American Intellectual Property Law Association (AIPLA) will be offering a web-based program on the "Effects of the AIA on Valuation, Licensing & Acquisitions" on February 15, 2012 from 12:30 - 1:30 pm (Eastern). Jeffrey Whittle and Michael Samardzija of Bracewell & Giuliani LLP will explore how the numerous changes to the patent system might affect valuation of patents, examine the various risks the new legislation provides in licensing and acquisition of patents, and provide ways to...
- Pfizer's Contraceptive Recall: A Statistical Needle in a Haystack!2 February 2012, 3:44 pm
... - Mining FDA's AER Database: Heaven for Hypochondriacs, Hell for Pharma1 February 2012, 2:43 pm
... - The Coming Pharma Digital Depression Caused by Facebook31 January 2012, 12:12 pm
... - Paula Deen & Victoza: Brilliant or Dumb?28 January 2012, 2:44 pm
...
- Unions Vow To Fight AstraZeneca Job Cuts3 February 2012, 6:54 pm
In the wake of the massive job cuts proposed by AstraZeneca, a pair of unions in the UK that represent employees at two facilities are vowing to fight the layoffs. The drugmaker, you may recall, announced plans earlier this week to eliminate 7,300 jobs in from facilites in various locations and divisions, including 2,200 from [...]... - Was NIMH Trial Rigged To Favor A Forest Drug?3 February 2012, 4:01 pm
In 2002, the National Institutes of Mental Health finalized a contract with the University of Texas Southwest Medical Center to run a 4,000-patient study of antidepressants at a cost of $35 million. The principal investigator chosen to run the year-long study was John Rush, a controversial figure who, at the time, was the professor and [...]... - Rick Santorum: “We’re Going To Ration Care”3 February 2012, 2:24 pm
video platformvideo managementvideo solutionsvideo player As the US grapples with an ailing economy, the notion of cost effectiveness of medicines has entered the Republican primary race. Although some people were concerned about rationing when the Obama administration introduced health care reform, Republican presidential contender Rick Santorum this week expressed support for the idea during what was [...]... - Up And Down The Ladder… Job Changes3 February 2012, 1:18 pm
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. [...]...
- Top HIV Vaccine Research Myths Busted17 November 2011, 10:28 pm
© avlxyzSince World Aids Day is almost here, December 1st, the HIV Vaccine Trials Network which is headquartered at Fred Hutchinson Cancer Research Center clarifies the most common myths about HIV vaccine research. A very prevalant myth is that HIV vaccines can give people AIDS - this is not true. The HIV vaccine does not contain the HIV virus and hence cannot give patients the disease. Another top myth is that there already exists an HIV vaccine, but there is no licensed vaccine against AIDS .... - Chickenpox Lollipops17 November 2011, 6:58 am
© BabyEksyDo you remember when you were in grade school and everyone's mom would schedule a play date with the kid with Chickenpox on a Saturday night? To an innocent second grader, this seemed like a fun filled night full of adventure and stories to tell at school on Monday. The only problem with telling the stories on Monday would be that there would be no school to attend. You would have to stay home, watch cartoons, and slather yourself in pink Calamine lotion for ...... - Chickenpox Lollipops17 November 2011, 6:58 am
© BabyEksyDo you remember when you were in grade school and everyone's mom would schedule a play date with the kid with Chickenpox on a Saturday night? To an innocent second grader, this seemed like a fun filled night full of adventure and stories to tell at school on Monday. The only problem with telling the stories on Monday would be that there would be no school to attend. You would have to stay home, watch cartoons, and slather yourself in pink Calamine lotion for ...... - Biotech Hemophilia Drug21 September 2011, 5:05 am
© erix!Biotech company Prolor has reported positive pre clinical trial results for its hemophilia drug known a Factor Vlla. The modified drug boasts a longer duration and half life of clotting activity versus current versions. The animal trials of Factor Vlla were conducted in hemophilic mice, and compared side by side with current versions of recombinant Factor Vlla. The advanced Factor Vlla-CTP showed significantly improved results as compared to the current commercial version of the drug,...
![[Facebook]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/facebook.png)
![[Google]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/google.png)
![[LinkedIn]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/linkedin.png)
![[Twitter]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/twitter.png)
![[Email]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/email.png)
